TG Therapeutics TGTX 深 沪
等待开盘 12-20 09:30:00 美东时间
31.25
+1.320
+4.41%
华盛通- 最 高31.25
- 今 开29.96
- 成交量 90.18万股
- 最 低 29.79
- 昨 收 29.93
- 总市值 49.69亿
- 52周最高 46.48
- 市盈率 静 214.33
- 换手率 0.57%
- 52周最低 25.28
- 委 比 56.10%
- 总股本 1.59亿
- 历史最高 56.74
- 量 比 1.77
- 振 幅 4.88%
- 历史最低 0.9563
- 每 手 1
- 风险率 3.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
TG Therapeutics' CEO, Michael S. Weiss, will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, with a fireside chat on December 2 at 12:30 PM ET. A live webcast will be available on the company's website. TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, including approved therapies like BRIUMVI® for multiple sclerosis. More information is available on their we...
11-28 12:30
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
TG Therapeutics ranked 27th on the 2025 Deloitte Technology Fast 500 list, highlighting its rapid growth driven by BRIUMVI® revenues, approved to treat multiple sclerosis in 2022. CEO Michael S. Weiss emphasized the company's commitment to innovation and improving care for autoimmune diseases.
11-19 13:30
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
11-12 01:35
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
TG Therapeutics' CEO, Michael S. Weiss, will participate in the TD Cowen Immunology & Inflammation Summit on November 12-13, 2025. A fireside chat is scheduled for November 12 at 10:00 AM ET, available via live webcast on the company's website. TG Therapeutics is a biopharmaceutical company focused on B-cell diseases and has received FDA approval for BRIUMVI® for treating multiple sclerosis. The company can be contacted via investor and media rel...
11-10 21:00
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
TG Therapeutics Q3 EPS $2.43 Beats $0.22 Estimate, Sales $161.709M Beat $152.169M Estimate
TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $2.43 per share which beat the analyst consensus estimate of $0.22 by 999.55 percent. This is a 12050 percent increase over earnings of $0.02 per share from
11-03 20:02
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Earnings Preview For TG Therapeutics
TG Therapeutics (NASDAQ:TGTX) will release its quarterly earnings report on Mon...
11-01 03:01
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
TG Therapeutics announced the completion of enrollment in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated dosing schedule for IV BRIUMVI in people with relapsing multiple sclerosis. The trial aims to assess non-inferior exposure compared to the existing regimen. BRIUMVI is currently approved for twice-yearly infusions and offers convenience among IV anti-CD20 treatments. TG plans to explore this simplified dosing regi...
10-28 11:30
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.
10-17 01:40
